{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:06:37Z","timestamp":1764601597925},"reference-count":29,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            is a frequent cause of acute endophthalmitis, and infection with this virulent bacterium is often associated with a poor visual outcome. In this study, we investigated the bactericidal efficacy and the safety of intravitreal daptomycin (DAP), a lipopeptide antibiotic with broad-spectrum activity against Gram-positive bacteria, compared with those of intravitreal vancomycin (VAN) in a methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            endophthalmitis rabbit model. The pharmacokinetics and pharmacodynamics of daptomycin in the infected eyes were also studied. Rabbits were randomly divided into three treatment groups (\n            <jats:italic>n<\/jats:italic>\n            = 8) and one untreated group (\n            <jats:italic>n<\/jats:italic>\n            = 4), to compare the effect of single intravitreal injections of 0.2 mg and 1 mg of daptomycin (DAP 0.2 and DAP 1 groups, respectively) with that of 1 mg of intravitreal vancomycin (VAN 1 group). Vitreal aspirates were regularly collected and grading of ocular inflammation was regularly performed until euthanasia on day 7. In the DAP 0.2 group, 62.5% of the eyes were sterilized and the mean bacterial count presented a reduction of 1 log unit. In the DAP 1 and VAN 1 groups, the infection was eradicated (100% and 87.5% of eyes sterilized, respectively), with a 4-log-unit reduction of the mean bacterial count. The bactericidal efficacy in the DAP 1 group was not inferior to that in the VAN 1 group and was superior to that of the other regimens in limiting the ocular inflammation and preserving the architecture of the ocular structures (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). The elimination half-life (\n            <jats:italic>t<\/jats:italic>\n            <jats:sub>1\/2\u03b2<\/jats:sub>\n            ) of daptomycin was independent of the administered dose (38.8 \u00b1 16.5 h and 40.9 \u00b1 6.7 h, respectively, for the DAP 0.2 and DAP 1 groups) and was significantly longer than the\n            <jats:italic>t<\/jats:italic>\n            <jats:sub>1\/2\u03b2<\/jats:sub>\n            of vancomycin (20.5 \u00b1 2.0 h for the VAN 1 group) (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). This antibiotic could therefore be considered for the treatment of intraocular infections caused by Gram-positive bacteria.\n          <\/jats:p>","DOI":"10.1128\/aac.05745-11","type":"journal-article","created":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T05:56:18Z","timestamp":1330408578000},"page":"2485-2492","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":16,"title":["Daptomycin versus Vancomycin in a Methicillin-Resistant Staphylococcus aureus Endophthalmitis Rabbit Model: Bactericidal Effect, Safety, and Ocular Pharmacokinetics"],"prefix":"10.1128","volume":"56","author":[{"given":"Sophie","family":"Lef\u00e8vre","sequence":"first","affiliation":[{"name":"Institute of Bacteriology, University of Strasbourg, Strasbourg, France"},{"name":"Department of Bacteriology, University Hospital of Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"Saleh","sequence":"additional","affiliation":[{"name":"Institute of Bacteriology, University of Strasbourg, Strasbourg, France"},{"name":"Department of Ophthalmology, University Hospital of Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Marcellin","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Subilia","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Bourcier","sequence":"additional","affiliation":[{"name":"Institute of Bacteriology, University of Strasbourg, Strasbourg, France"},{"name":"Department of Ophthalmology, University Hospital of Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Pr\u00e9vost","sequence":"additional","affiliation":[{"name":"Institute of Bacteriology, University of Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Jehl","sequence":"additional","affiliation":[{"name":"Institute of Bacteriology, University of Strasbourg, Strasbourg, France"},{"name":"Department of Bacteriology, University Hospital of Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Antibiogram Committee of the French Microbiology Society. 2010 recommendations. Antibiogram Committee of the French Microbiology Society Paris France. http:\/\/www.sfm-microbiologie.org\/UserFiles\/file\/CASFM\/casfm_2010.pdf."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(20)30288-9"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(82)90080-7"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0924-8579(97)00035-6","article-title":"Contribution of animal models of infection for the evaluation of the activity of antimicrobial agents","volume":"9","author":"Belmatoug N","year":"1997","unstructured":"BelmatougN FantinB. 1997. Contribution of animal models of infection for the evaluation of the activity of antimicrobial agents. Int. J. Antimicrob. Agents 9:73\u201382.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00247-06"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.7.1054"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.470-472.2005"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/IAE.0b013e318207d1b9","article-title":"Intravitreal daptomycin: a safety and efficacy study","volume":"31","author":"Comer GM","year":"2011","unstructured":"ComerGM. 2011. Intravitreal daptomycin: a safety and efficacy study. Retina 31:1199\u20131206.","journal-title":"Retina"},{"key":"e_1_3_2_10_2","first-page":"1373","article-title":"Epidemiology of infective endophthalmitis in France. The French Collaborative Study Group on Endophthalmitis","volume":"338","author":"Fisch A","year":"1991","unstructured":"FischA. 1991. Epidemiology of infective endophthalmitis in France. The French Collaborative Study Group on Endophthalmitis. Lancet 338:1373\u20131376.","journal-title":"Lancet"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ajo.2007.03.032","article-title":"Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus","volume":"144","author":"Freidlin J","year":"2007","unstructured":"FreidlinJ. 2007. Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus. Am. J. Ophthalmol. 144:313\u2013315.","journal-title":"Am. J. Ophthalmol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.203-208.2004"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)71959-2"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/14656561003598893","article-title":"Daptomycin: pharmacology and clinical use","volume":"11","author":"Kosmidis C","unstructured":"KosmidisC LevineDP. Daptomycin: pharmacology and clinical use. Expert Opin. Pharmacother. 11:615\u2013625.","journal-title":"Expert Opin. Pharmacother."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.845-851.2001"},{"key":"e_1_3_2_16_2","first-page":"1085","article-title":"Intraocular penetration of oral levofloxacin in rabbits","volume":"98","author":"Mochizuki K","year":"1994","unstructured":"MochizukiK. 1994. Intraocular penetration of oral levofloxacin in rabbits. Nihon Ganka Gakkai Zasshi 98:1085\u20131090. (In Japanese.)","journal-title":"Nihon Ganka Gakkai Zasshi"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1586\/eop.10.52","article-title":"Severe bacterial endophthalmitis: towards improving clinical outcomes","volume":"5","author":"Novosad BD","unstructured":"NovosadBD CalleganMC. Severe bacterial endophthalmitis: towards improving clinical outcomes. Expert Rev. Ophthalmol. 5:689\u2013698.","journal-title":"Expert Rev. Ophthalmol."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt RB","year":"1985","unstructured":"NussenblattRB PalestineAG ChanCC RobergeF. 1985. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92:467\u2013471.","journal-title":"Ophthalmology"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100100112040"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jac\/dkf178","article-title":"Pharmacokinetics and ocular penetration of grepafloxacin in albino and pigmented rabbits","volume":"50","author":"Perez S","year":"2002","unstructured":"PerezS. 2002. Pharmacokinetics and ocular penetration of grepafloxacin in albino and pigmented rabbits. J. Antimicrob. Chemother. 50:541\u2013545.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_21_2","first-page":"45","article-title":"Postoperative endophthalmitis: a comparison of methods for treatment and prophylaxis with gentamicin","volume":"6","author":"Peyman GA","year":"1975","unstructured":"PeymanGA PaqueJT MeiselsHI BennettTO. 1975. Postoperative endophthalmitis: a comparison of methods for treatment and prophylaxis with gentamicin. Ophthalmic Surg. 6:45\u201355.","journal-title":"Ophthalmic Surg."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1055\/s-2008-1035237","article-title":"Toxic retinopathy caused by intravitreal injection of amikacin and vancomycin","volume":"208","author":"Piguet B","year":"1996","unstructured":"PiguetB ChobazC GrounauerPA. 1996. Toxic retinopathy caused by intravitreal injection of amikacin and vancomycin. Klin. Monbl. Augenheilkd. 208:358\u2013359. (In French.)","journal-title":"Klin. Monbl. Augenheilkd."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.63-68.2004"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1442-9071.1996.tb01569.x","article-title":"Macula toxicity after intravitreal amikacin","volume":"24","author":"Seawright AA","year":"1996","unstructured":"SeawrightAA BourkeRD CoolingRJ. 1996. Macula toxicity after intravitreal amikacin. Aust. N. Z. J. Ophthalmol. 24:143\u2013146.","journal-title":"Aust. N. Z. J. Ophthalmol."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1592\/phco.30.12.1247","article-title":"Presence of adequate intravitreal concentrations of daptomycin after systemic intravenous administration in a patient with endogenous endophthalmitis","volume":"30","author":"Sheridan KR","unstructured":"SheridanKR PotoskiBA ShieldsRK NauGJ. Presence of adequate intravitreal concentrations of daptomycin after systemic intravenous administration in a patient with endogenous endophthalmitis. Pharmacotherapy 30:1247\u20131251.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/527392"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1023\/A:1026451721686","article-title":"Confidence interval criteria for assessment of dose proportionality","volume":"17","author":"Smith BP","year":"2000","unstructured":"SmithBP. 2000. Confidence interval criteria for assessment of dose proportionality. Pharm. Res. 17:1278\u20131283.","journal-title":"Pharm. Res."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0161-6420(86)33579-6","article-title":"Treatment of experimental methicillin-resistant Staphylococcus epidermidis endophthalmitis with intravitreal vancomycin","volume":"93","author":"Smith MA","year":"1986","unstructured":"SmithMA. 1986. Treatment of experimental methicillin-resistant Staphylococcus epidermidis endophthalmitis with intravitreal vancomycin. Ophthalmology 93:1328\u20131335.","journal-title":"Ophthalmology"},{"key":"e_1_3_2_29_2","first-page":"303","article-title":"Postoperative endophthalmitis: incidence, predisposing surgery, clinical course and outcome","volume":"32","author":"Somani S","year":"1997","unstructured":"SomaniS GrinbaumA SlomovicAR. 1997. Postoperative endophthalmitis: incidence, predisposing surgery, clinical course and outcome. Can. J. Ophthalmol. 32:303\u2013310.","journal-title":"Can. J. Ophthalmol."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0732-8893(90)90067-6","article-title":"Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies","volume":"13","author":"Stratton CW","year":"1990","unstructured":"StrattonCW WeeksLS. 1990. Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies. Diagn. Microbiol. Infect. Dis. 13:245\u2013252.","journal-title":"Diagn. Microbiol. Infect. Dis."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05745-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05745-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:53:32Z","timestamp":1645480412000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.05745-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1128\/AAC.05745-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.05745-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"2011-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-02-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}